Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to p...
Enregistré dans:
Auteurs principaux: | , , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Radcliffe Medical Media
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/58046a30dfdd462285494bac6b076e2c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|